Showing results (91-100 of 294) with videos related to
Sort By:
Pageof 30
Contemporary Clinical Trials|November 16, 2019
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trialMarcos Pedrosa, Star Seyedkazemi, Sven Francque, et al.The Lancet Regional Health. Europe|January 8, 2024
Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort studyQuentin M Anstee, Tina L Berentzen, Louise M Nitze, et al.Journal of Clinical Medicine|May 28, 2022
Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method StudyYasaman Vali, Roel Eijk, Timothy Hicks, et al.Contemporary Clinical Trials|July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitisVlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.The Lancet. Gastroenterology & Hepatology|August 3, 2025
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy studyVincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, et al.Eclinicalmedicine|December 7, 2023
FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialVincent Wai-Sun Wong, Quentin M Anstee, Louise M Nitze, et al.Journal of Hepatology|May 24, 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation studyStephen A Harrison, Vlad Ratziu, Jeremy Magnanensi, et al.Npj Metabolic Health and Disease|July 3, 2025
ECM formation and degradation during fibrosis, repair, and regenerationAlejandro E Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, et al.Gerontology|August 20, 2009
Non-alcoholic fatty liver disease in older peopleJames Frith, Christopher P Day, Elsbeth Henderson, et al.Journal of Hepatology|April 11, 2020
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysisYasaman Vali, Jenny Lee, Jérôme Boursier, et al.Pageof 30